RT Journal Article
T1 European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients.
A1 Nyssen, Olga P
A1 Bordin, Dmitry
A1 Tepes, Bojan
A1 Pérez-Aisa, Ángeles
A1 Vaira, Dino
A1 Caldas, Maria
A1 Bujanda, Luis
A1 Castro-Fernandez, Manuel
A1 Lerang, Frode
A1 Leja, Marcis
A1 Rodrigo, Luís
A1 Rokkas, Theodore
A1 Kupcinskas, Limas
A1 Pérez-Lasala, Jorge
A1 Jonaitis, Laimas
A1 Shvets, Oleg
A1 Gasbarrini, Antonio
A1 Simsek, Halis
A1 Axon, Anthony T R
A1 Buzás, György
A1 Machado, Jose Carlos
A1 Niv, Yaron
A1 Boyanova, Lyudmila
A1 Goldis, Adrian
A1 Lamy, Vincent
A1 Tonkic, Ante
A1 Przytulski, Krzysztof
A1 Beglinger, Christoph
A1 Venerito, Marino
A1 Bytzer, Peter
A1 Capelle, Lisette
A1 Milosavljević, Tomica
A1 Milivojevic, Vladimir
A1 Veijola, Lea
A1 Molina-Infante, Javier
A1 Vologzhanina, Liudmila
A1 Fadeenko, Galina
A1 Ariño, Ines
A1 Fiorini, Giulia
A1 Garre, Ana
A1 Garrido, Jesús
A1 F Pérez, Cristina
A1 Puig, Ignasi
A1 Heluwaert, Frederic
A1 Megraud, Francis
A1 O'Morain, Colm
A1 Gisbert, Javier P
A1 Hp-EuReg Investigators, 
K1 helicobacter pylori
K1 helicobacter pylori - treatment
AB The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care. International multicentre prospective non-interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events and outcomes. Data monitoring was performed to ensure data quality. Time-trend and geographical analyses were performed. 30 394 patients from 27 European countries were evaluated and 21 533 (78%) first-line empirical H. pylori treatments were included for analysis. Pretreatment resistance rates were 23% to clarithromycin, 32% to metronidazole and 13% to both. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (39%), achieving 81.5% modified intention-to-treat eradication rate. Over 90% eradication was obtained only with 10-day bismuth quadruple or 14-day concomitant treatments. Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates. Time-trend analysis showed a region-dependent shift in prescriptions including abandoning triple therapies, using higher acid-inhibition and longer treatments, which was associated with an overall effectiveness increase (84%-90%). Management of H. pylori infection by European gastroenterologists is heterogeneous, suboptimal and discrepant with current recommendations. Only quadruple therapies lasting at least 10 days are able to achieve over 90% eradication rates. European recommendations are being slowly and heterogeneously incorporated into routine clinical practice, which was associated with a corresponding increase in effectiveness.
YR 2020
FD 2020-09-21
LK http://hdl.handle.net/10668/16292
UL http://hdl.handle.net/10668/16292
LA en
DS RISalud
RD Mar 13, 2025